TTR · Western blot design guide

TTR Western Blot Planning Guide

Plan a TTR Western blot around the catalog-observed 15.9 kDa band, image-backed PB9749 evidence, HPA controls, and verified protocol records.

Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for TTR (TTR): expected band 15.9 kDa, antibody PB9749, and guide-derived SDS-PAGE protocol steps
TTR Western blot protocol sheet — expected band 15.9 kDa, antibody PB9749, controls and PMC citations. Open the full TTR WB guide →

TTR Western Blot Experimental Design Guide

Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band 15.9 kDa
Observed band Not reported — verify product WB image
Gel 15%
Positive control ⓘ Liver
Negative control ⓘ Adrenal gland
Important caveats
Reasons your observed band may differ from the expected size.
ⓘ Calculated mass 15.9 kDa
ⓘ Localization Secreted / Cytoplasm
ⓘ Processing / PTM Record-dependent
ⓘ Reactivity Human
Section 1

Real Curated TTR Western Blot Protocols

Start with the molecular-weight rule, then compare verified publication-derived conditions.

Recommended Western blot protocol parameters
Sample / lysateChoroid plexus
Gel %15%
Load20-30 µg total protein per lane
TransferSemi-dry, short transfer
Membrane0.2 µm PVDF
Blocking5% non-fat milk or 5% BSA in TBST
PrimaryPB9749 at datasheet starting dilution
Primary incubationOvernight at 4 °C with gentle agitation
SecondarySpecies-matched HRP conjugate at validated dilution
Wash3 × 5 min in TBST
DetectionChemiluminescent substrate
ExposureBracket exposures to avoid saturation
Section 2

What Is the Expected TTR Western Blot Band Size?

Use the product-observed 15.9 kDa band as the primary planning value and retain the UniProt calculated mass as context.

What am I looking at on my blot?
15.9 kDaMatches the authoritative product WB observation.
15.9 kDa calculatedUse as UniProt context, not as a replacement observed band.
Unexpected additional signalDo not assign identity without orthogonal positive/negative controls.
💡Expected TTR appearancePlan around 15.9 kDa and keep the calculated mass as supporting context.
How each factor affects band size
Catalog-observed band15.9 kDa; use this as the primary experimental expectation.
Calculated mass15.9 kDa from UniProt P02766; retain as context.
Gel selection15%; shared with the recommended protocol and poster.
Specificity checkCompare the lead HPA positive and negative controls with PB9749.
Why is my band missing or off?
SituationLikely causeNext action
15.9 kDaMatches the authoritative product WB observation.Confirm with orthogonal controls and the linked product record.
Additional bandMay reflect processing, modification, or non-specific signal.Run a dilution series and compare positive/negative controls.
Weak signalTarget abundance or transfer may be limiting.Verify transfer, increase positive-control abundance, and bracket exposure.

Sample controls for TTR Western blot

🧪Use Liver as the first positive-control candidate and Adrenal gland as the HPA Not detected negative candidate.
Positive control: Liver (Medium)
Negative control: Adrenal gland (Not detected)
HPA protein score determines control status; other expression data is supporting context only.

HPA tissue expression evidence for TTR

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

TissueCell typeLevelEvidenceSource
Liver Reported tissue cells Medium Protein (HPA) HPA →
Pancreas Reported tissue cells Medium Protein (HPA) HPA →
Choroid plexus Reported tissue cells Medium Protein (HPA) HPA →
Kidney Reported tissue cells Low Protein (HPA) HPA →

Undetected expression · recommended negative controls

TissueCell typeLevelEvidenceSource
Adrenal gland Reported tissue cells Not detected Protein (HPA) HPA →
Appendix Reported tissue cells Not detected Protein (HPA) HPA →
Section 3

Advanced TTR Western Blot Tips

Deeper troubleshooting and optimisation questions for TTR, answered from its protein features.

Which band should guide the blot?
Use 15.9 kDa, the observation attached to the authoritative PB9749 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 15.9 kDa expectation.
Which positive control should I start with?
Start with Liver, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Adrenal gland as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for TTR Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PB9749 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents

TTR Western Blot Reagents

Human-reactive TTR Western blot reagents with authoritative product imagery.

Real WB data Western blot validation image for TTR using PB9749; observed band 15.9 kDa
Anti-Prealbumin/TTR Antibody Picoband®
Cat # PB9749

Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.

Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.

References

  1. UniProt P02766
  2. Human Protein Atlas — TTR
  3. PB9749 product record
  4. PMC12625856 — Amino acid insufficiency impairs hepatic vitamin A mobilization in mice (Proceedings of the National Academy of Sciences of the United States of America, 2025)
  5. PMC4222630 — Curcumin could reduce the monomer of TTR with Tyr114Cys mutation via autophagy in cell model of familial amyloid polyneuropathy (Drug design, development and therapy, 2014)